Mirikizumab Demonstrates Rapid Improvements in Bowel Urgency Severity, Bowel Urgency Frequency, and Stool Deferral Time in Patients with Moderately-to-severely Active Ulcerative Colitis: 12-Week Interim Results from the Phase 3b LUCENT-URGE Trial